Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BASF debuts omega-3 medical food

by Rick Mullin
March 5, 2018 | A version of this story appeared in Volume 96, Issue 10

[+]Enlarge
Credit: BASF
BASF's new medical food.
Credit: BASF

BASF is entering the medical food market with the launch of a product for people with nonalcoholic fatty liver disease (NAFLD). Hepaxa, a pill containing highly concentrated and pure omega-3 acids—eicosapentaenoic and docosahexaenoic acids—is being called the first product in the U.S. designed to address a buildup of fat in the liver, known as steatosis, in people with NAFLD. Diem Labs will distribute it. The two firms announced an agreement last year to work together in the medical food arena.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.